FDA Inspection 1261706 — The Center for Reproductive Endocrinology

The Center for Reproductive Endocrinology — FEI 3003927090

The FDA completed an inspection of The Center for Reproductive Endocrinology on February 12, 2025 in Dallas, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
February 12, 2025
Fiscal Year
2025
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Dallas, TX (United States)